Literature DB >> 294697

Sclerotic medullary spread in diaphyseal osteosarcoma.

J M Haworth, I W McCall, W M Park, I Watt.   

Abstract

Dense medullary sclerosis is reported in the shafts of long bones accompanying diaphyseal osteosarcoma. Histological evidence suggests that this indicates more extensive medullary spread of tumour than is readily apparent on standard radiographic examination. It would appear that these sclerotic lesions show active radio-isotopes retention following skeletal scintigraphy. The clinical and radiological features and prognostic implications of these findings are discussed.

Entities:  

Mesh:

Year:  1979        PMID: 294697     DOI: 10.1007/bf00347215

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  5 in total

1.  The implications of "skip" metastases in osteosarcoma.

Authors:  W F Enneking; A Kagan
Journal:  Clin Orthop Relat Res       Date:  1975-09       Impact factor: 4.176

2.  Extension of primary neoplasms of bone to bone marrow.

Authors:  J E UPSHAW; J R McDONALD; R K GHORMLEY
Journal:  Surg Gynecol Obstet       Date:  1949-12

3.  Proceedings: Medullary extension of osteosarcoma. Implications for rational therapy.

Authors:  R J Lewis; M J Lotz
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

4.  Osteogenic sarcoma. A study of six hundred cases.

Authors:  D C Dahlin; M B Coventry
Journal:  J Bone Joint Surg Am       Date:  1967-01       Impact factor: 5.284

5.  Metastatic spread of osteosarcoma.

Authors:  C H Price; G M Jeffree
Journal:  Br J Cancer       Date:  1973-12       Impact factor: 7.640

  5 in total
  1 in total

Review 1.  Diagnosis and treatment of intramedullary osteosclerosis: a report of three cases and literature review.

Authors:  Kensaku Abe; Norio Yamamoto; Katsuhiro Hayashi; Akihiko Takeuchi; Shinji Miwa; Kentaro Igarashi; Takashi Higuchi; Yuta Taniguchi; Hirotaka Yonezawa; Yoshihiro Araki; Sei Morinaga; Yohei Asano; Hiroyuki Tsuchiya
Journal:  BMC Musculoskelet Disord       Date:  2020-11-19       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.